2020年美国青少年疫苗接种覆盖率:国家、地区、州及部分地方区域分析
CDC分析2020年国家青少年免疫调查(NIS-Teen)中20,163名13-17岁青少年数据,估计推荐疫苗接种覆盖率。HPV疫苗≥1剂覆盖率从2019年71.5%升至2020年75.1%,HPV完成率从54.2%升至58.6%;Tdap、MenACWY覆盖率和2019年相似。COVID-19大流行干扰了常规免疫服务,但2020年NIS-Teen反映的是大流行前的接种情况。
要点
- 2020年13-17岁青少年HPV疫苗≥1剂覆盖率为75.1%,完成率为58.6%,均较2019年上升。
- Tdap≥1剂覆盖率90.1%,MenACWY≥1剂覆盖率89.3%,17岁青少年MenACWY≥2剂覆盖率54.4%,与2019年相似。
- 贫困线以下青少年HPV疫苗覆盖率高于贫困线及以上青少年;非大都市统计区青少年MenACWY和HPV覆盖率较低。
核心结论
- 2020年美国青少年HPV疫苗接种覆盖率较2019年上升,Tdap和MenACWY覆盖率保持稳定,但COVID-19大流行对常规免疫服务的干扰需持续关注。
研究设计与样本
- CDC分析了2020年国家青少年免疫调查(NIS-Teen)中20,163名13-17岁青少年的数据,以估计推荐疫苗接种覆盖率。
主要发现
- HPV疫苗≥1剂覆盖率从2019年71.5%升至2020年75.1%,HPV完成率(HPV UTD)从54.2%升至58.6%。
- Tdap≥1剂覆盖率90.1%,MenACWY≥1剂覆盖率89.3%,17岁青少年MenACWY≥2剂覆盖率54.4%,均与2019年相似。
- 13-17岁青少年HepA≥2剂覆盖率和17岁青少年MenB≥1剂覆盖率上升。
- 贫困线以下青少年HPV疫苗覆盖率高于贫困线及以上青少年;非大都市统计区青少年MenACWY≥1剂和HPV≥1剂覆盖率及HPV完成率低于大都市统计区主要城市青少年。
关键数值与推荐
- ACIP建议11-12岁青少年常规接种Tdap、MenACWY和HPV疫苗;对乙肝、甲肝、麻腮风和水痘疫苗 childhood 接种不完整者进行补种。
- 建议16岁青少年接种MenACWY加强剂,16-23岁人群可经共享临床决策接种B群脑膜炎球菌疫苗(MenB)。
临床怎么用
- 2020年NIS-Teen数据可用于评估COVID-19大流行对补种疫苗接种的影响,但不适用于评估对常规青少年疫苗接种的影响,因调查对象≥13岁且多数接种发生在2020年3月前。
- 需持续努力覆盖常规医疗受COVID-19大流行影响的青少年,以预防疫苗可预防疾病和疫情。
局限性
- 2020年NIS-Teen反映的是COVID-19大流行前的青少年疫苗接种覆盖率。
- 调查对象年龄≥13岁,已超过大多数常规青少年疫苗推荐接种年龄,且多数接种发生在2020年3月前,故不能用于评估大流行对常规青少年疫苗接种的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents aged 11-12 years routinely receive tetanus, diphtheria, and acellular pertussis (Tdap); meningococcal conjugate (MenACWY); and human papillomavirus (HPV) vaccines. Catch-up vaccination is recommended for hepatitis B (HepB); hepatitis A (HepA); measles, mumps, and rubella (MMR); and varicella (VAR) vaccines for adolescents whose childhood vaccinations are not current. Adolescents are also recommended to receive a booster dose of MenACWY vaccine at age 16 years, and shared clinical decision-making is recommended for the serogroup B meningococcal vaccine (MenB) for persons aged 16-23 years (1). To estimate coverage with recommended vaccines, CDC analyzed data from the 2020 National Immunization Survey-Teen (NIS-Teen) for 20,163 adolescents aged 13-17 years.* Coverage with ≥1 dose of HPV vaccine increased from 71.5% in 2019 to 75.1% in 2020. The percentage of adolescents who were up to date† with HPV vaccination (HPV UTD) increased from 54.2% in 2019 to 58.6% in 2020. Coverage with ≥1 dose of Tdap, ≥1 dose (and among adolescents aged 17 years, ≥2 doses) of MenACWY remained similar to coverage in 2019 (90.1%, 89.3%, and 54.4% respectively). Coverage increased for ≥2 doses of HepA among adolescents aged 13-17 years and ≥1 dose of MenB among adolescents aged 17 years. Adolescents living below the federal poverty level§ had higher HPV vaccination coverage than adolescents living at or above the poverty level. Adolescents living outside a metropolitan statistical area (MSA)¶ had lower coverage with ≥1 MenACWY and ≥1 HPV dose, and a lower proportion being HPV UTD than adolescents in MSA principal cities. In 2020, the COVID-19 pandemic disrupted routine immunization services. Results from the 2020 NIS-Teen reflect adolescent vaccination coverage before the COVID-19 pandemic. The 2020 NIS-Teen data could be used to assess the impact of the COVID-19 pandemic on catch-up vaccination but not on routine adolescent vaccination because adolescents included in the survey were aged ≥13 years, past the age when most routine adolescent vaccines are recommended, and most vaccinations occurred before March 2020. Continued efforts to reach adolescents whose routine medical care has been affected by the COVID-19 pandemic are necessary to protect persons and communities from vaccine-preventable diseases and outbreaks.
引用
- Pingali C, Yankey D, Elam-Evans LD, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2020. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34473682. doi:10.15585/mmwr.mm7035a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。